News|Articles|July 29, 2026

What FDA's Peptide Decision Means for the Industry

An FDA advisory panel voted to recommend six of seven unapproved peptides for compounding access, raising concerns about its newly appointed members.

In a two-day meeting that exposed deep fault lines, an FDA advisory committee voted to recommend that compounding pharmacies be allowed to manufacture six of seven unapproved peptides under review.

Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.